"text","label","instanceType","uuid:ID","id","description","name"
"To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","","Objective","a47784c0-d79f-4b2e-8e8a-be981bc6416f","Objective_1","Main objective","OBJ1"
"To document the safety profile of the xanomeline TTS.","","Objective","82994a3c-9522-48fe-b4d1-2cc06d372008","Objective_2","Safety","OBJ2"
"To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","","Objective","676f8b06-4859-463f-ae6a-f11acbe28783","Objective_3","Behaviour","OBJ3"
"To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","","Objective","ee02950f-16ed-44bb-9cce-d1c5f85ffc61","Objective_4","","OBJ4"
"To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","","Objective","9b8b8707-04f7-4199-8f5d-54d1fd3e6a9b","Objective_5","","OBJ5"
"To assess the treatment response as a function of Apo E genotype.","","Objective","ed69391b-dfed-4583-86e9-2034ed6b6fd5","Objective_6","","OBJ6"
